Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)

NCT04412018 is registered in ClinicalTrials.gov with Canadian Medical and Surgical Knowledge Translation Research Group as lead sponsor.

NCT NCT04412018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04412018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)
Lead sponsor
Canadian Medical and Surgical Knowledge Translation Research Group
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2020
Completion date
December 12, 2020
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, inflammatory response